Literature DB >> 34327632

Epigallocatechin Gallate Alleviates Down-Regulation of Thioredoxin in Ischemic Brain Damage and Glutamate-Exposed Neuron.

Dong-Ju Park1, Ju-Bin Kang1, Murad-Ali Shah1, Phil-Ok Koh2.   

Abstract

Epigallocatechin gallate (EGCG) is one of polyphenol that is abundant in green tea. It has anti-oxidative activity and exerts neuroprotective effects in ischemic brain damage. Ischemic conditions induce oxidative stress and result in cell death. Thioredoxin is a small redox protein that plays an important role in the regulation of oxidation and reduction. This study was designed to investigate the regulation of thioredoxin by EGCG in ischemic brain damage. Middle cerebral artery occlusion (MCAO) was performed to induce focal cerebral ischemia in male Sprague-Dawley rats. The EGCG (50 mg/kg) or was administered before MCAO surgical operation. Neurological behavior test, reactive oxygen species (ROS), and lipid peroxidation (LPO) measurement were performed 24 h after MCAO. The cerebral cortex was isolated for further experiments. EGCG alleviated MCAO-induced neurological deficits and increases in ROS and LPO levels. EGCG also ameliorated the decrease in thioredoxin expression by MCAO. This finding was confirmed using various techniques such as Western blot analysis, reverse transcription PCR, and immunofluorescence staining. Results of immunoprecipitation showed that MCAO decreases the interaction between apoptosis signal-regulating kinase 1 (ASK1) and thioredoxin, while EGCG treatment attenuates this decrease. EGCG also attenuated decrease of cell viability and thioredoxin expression in glutamate-exposed neuron in a dose-dependent manner. It alleviated the increase of caspase-3 by glutamate exposure. However, this effect of EGCG on caspase-3 change was weakened in thioredoxin siRNA-transfected neurons. These findings suggest that EGCG exerts a neuroprotective effect by regulating thioredoxin expression and modulating ASK1 and thioredoxin binding in ischemic brain damage.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cerebral ischemia; Epigallocatechin gallate; Glutamate; Neuroprotection; Thioredoxin

Mesh:

Substances:

Year:  2021        PMID: 34327632     DOI: 10.1007/s11064-021-03403-0

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  53 in total

1.  Catechin contents of foods commonly consumed in The Netherlands. 1. Fruits, vegetables, staple foods, and processed foods.

Authors:  I C Arts; B van de Putte; P C Hollman
Journal:  J Agric Food Chem       Date:  2000-05       Impact factor: 5.279

2.  The pharmacological activity of epigallocatechin-3-gallate (EGCG) on Alzheimer's disease animal model: A systematic review.

Authors:  Shuang Zhang; Qi Zhu; Jia-Yue Chen; Defang OuYang; Jia-Hong Lu
Journal:  Phytomedicine       Date:  2020-08-31       Impact factor: 5.340

3.  Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.

Authors:  Saverio Bettuzzi; Maurizio Brausi; Federica Rizzi; Giovanni Castagnetti; Giancarlo Peracchia; Arnaldo Corti
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

4.  Increased BBB permeability contributes to EGCG-caused cognitive function improvement in natural aging rats: pharmacokinetic and distribution analyses.

Authors:  Bin-Bin Wei; Ming-Yan Liu; Xin Zhong; Wei-Fan Yao; Min-Jie Wei
Journal:  Acta Pharmacol Sin       Date:  2019-05-15       Impact factor: 6.150

5.  (-)-Epigallocatechin-3-gallate provides neuroprotection via AMPK activation against traumatic brain injury in a mouse model.

Authors:  Yinyin Wu; Jing Cui
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-02-15       Impact factor: 3.000

6.  Epigallocatechin Gallate (EGCG) Inhibits Alpha-Synuclein Aggregation: A Potential Agent for Parkinson's Disease.

Authors:  Yan Xu; Yanyan Zhang; Zhenzhen Quan; Winnie Wong; Jianping Guo; Rongkai Zhang; Qinghu Yang; Rongji Dai; Patrick L McGeer; Hong Qing
Journal:  Neurochem Res       Date:  2016-06-30       Impact factor: 3.996

7.  Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue.

Authors:  M Suganuma; S Okabe; M Oniyama; Y Tada; H Ito; H Fujiki
Journal:  Carcinogenesis       Date:  1998-10       Impact factor: 4.944

8.  (-)-Epigallocatechin gallate (EGCG)-nanoethosomes as a transdermal delivery system for docetaxel to treat implanted human melanoma cell tumors in mice.

Authors:  Bingwu Liao; Hao Ying; Chenhuan Yu; Zhaoyang Fan; Weihua Zhang; John Shi; Huazhong Ying; Nagaiya Ravichandran; Yongquan Xu; Junfeng Yin; Yongwen Jiang; Qizhen Du
Journal:  Int J Pharm       Date:  2016-08-18       Impact factor: 5.875

9.  Blood brain barrier permeability of (-)-epigallocatechin gallate, its proliferation-enhancing activity of human neuroblastoma SH-SY5Y cells, and its preventive effect on age-related cognitive dysfunction in mice.

Authors:  Monira Pervin; Keiko Unno; Aimi Nakagawa; Yuu Takahashi; Kazuaki Iguchi; Hiroyuki Yamamoto; Minoru Hoshino; Aya Hara; Akiko Takagaki; Fumio Nanjo; Akira Minami; Shinjiro Imai; Yoriyuki Nakamura
Journal:  Biochem Biophys Rep       Date:  2017-01-05

10.  Epigallocatechin gallate alleviates neuronal cell damage against focal cerebral ischemia in rats.

Authors:  Dong-Ju Park; Ju-Bin Kang; Phil-Ok Koh
Journal:  J Vet Med Sci       Date:  2020-03-30       Impact factor: 1.267

View more
  2 in total

Review 1.  Polyphenols for the Treatment of Ischemic Stroke: New Applications and Insights.

Authors:  Shuhan Liu; Feng Lin; Jian Wang; Xiaoqiang Pan; Liguang Sun; Wei Wu
Journal:  Molecules       Date:  2022-06-29       Impact factor: 4.927

Review 2.  The Role of the NRF2 Pathway in Maintaining and Improving Cognitive Function.

Authors:  Nora E Gray; Marcelo Farina; Paolo Tucci; Luciano Saso
Journal:  Biomedicines       Date:  2022-08-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.